Company News

Bioscreen RIPT Panel Starts Dec. 19

Determines a product's skin sensitization and allergy development.

Author Image

By: TOM BRANNA

Editor

Bioscreen Clinical Services’ safety & efficacy testing RIPT panel begins on Dec. 19. The RIPT test is the industry standard safety testto determine the potential for skin sensitization and allergy development in a product. Upon completion of the Repeat Insult Patch Test the following claims may be valid after meeting certain criteria: • Non-Irritating • Clinically Tested • Allergy Tested If no allergenic reactions are observed, optional dermatologist involvement in study all...

Continue reading this story and get 24/7 access to Happi for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Happi Newsletters